PURPOSE: Microalbuminuria (MA) is a risk factor for cardiovascular disease (CVD). It is not known whether this association is due to the effect of MA on the development of subclinical atherosclerosis or whether MA destabilizes subclinical atherosclerosis, leading to clinical events. METHODS: In a cross-sectional analysis we evaluated 3312 Cardiovascular Health Study participants, age >or=65 years, who had MA testing. Participants were divided into three groups: those without diabetes or hypertension (33%), those with hypertension (52%) and those with diabetes, with or without hypertension (15%). Clinical CVD was defined as presence of coronary heart disease (angina, MI, CABG, PTCA), cerebrovascular disease (stroke, TIA) and peripheral arterial disease (requiring intervention). Among those without clinical disease, subclinical atherosclerosis was defined as increased carotid artery intima-media thickness, decreased ankle arm index or increased left ventricular mass. RESULTS: In each of the three groups of participants, the adjusted odds of prevalent clinical CVD in the presence of MA was 1.70-1.80-fold increased, independent of other risk factors. MA was not associated with risk of subclinical atherosclerosis in those without hypertension or diabetes (OR 1.14 [95% CI 0.59, 2.23]), whereas it was associated with subclinical atherosclerosis in those with hypertension (OR 1.58 [95% CI 1.08, 2.30]) or diabetes (OR 2.51 [95% CI 1.27, 4.94]). CONCLUSION: In the absence of hypertension or diabetes, MA was associated with clinical CVD but not with subclinical atherosclerosis. Thus, a hypothesis may be made that the mechanism of association of MA with clinical vascular disease involves destabilization of the vasculature, leading to clinical disease.
PURPOSE: Microalbuminuria (MA) is a risk factor for cardiovascular disease (CVD). It is not known whether this association is due to the effect of MA on the development of subclinical atherosclerosis or whether MA destabilizes subclinical atherosclerosis, leading to clinical events. METHODS: In a cross-sectional analysis we evaluated 3312 Cardiovascular Health Study participants, age >or=65 years, who had MA testing. Participants were divided into three groups: those without diabetes or hypertension (33%), those with hypertension (52%) and those with diabetes, with or without hypertension (15%). Clinical CVD was defined as presence of coronary heart disease (angina, MI, CABG, PTCA), cerebrovascular disease (stroke, TIA) and peripheral arterial disease (requiring intervention). Among those without clinical disease, subclinical atherosclerosis was defined as increased carotid artery intima-media thickness, decreased ankle arm index or increased left ventricular mass. RESULTS: In each of the three groups of participants, the adjusted odds of prevalent clinical CVD in the presence of MA was 1.70-1.80-fold increased, independent of other risk factors. MA was not associated with risk of subclinical atherosclerosis in those without hypertension or diabetes (OR 1.14 [95% CI 0.59, 2.23]), whereas it was associated with subclinical atherosclerosis in those with hypertension (OR 1.58 [95% CI 1.08, 2.30]) or diabetes (OR 2.51 [95% CI 1.27, 4.94]). CONCLUSION: In the absence of hypertension or diabetes, MA was associated with clinical CVD but not with subclinical atherosclerosis. Thus, a hypothesis may be made that the mechanism of association of MA with clinical vascular disease involves destabilization of the vasculature, leading to clinical disease.
Authors: M I Aguilar; E S O'Meara; S Seliger; W T Longstreth; R G Hart; P E Pergola; M G Shlipak; R Katz; M J Sarnak; D E Rifkin Journal: Neurology Date: 2010-09-01 Impact factor: 9.910
Authors: Dena E Rifkin; Ronit Katz; Michel Chonchol; Linda F Fried; Jie Cao; Ian H de Boer; David S Siscovick; Michael G Shlipak; Mark J Sarnak Journal: Nephrol Dial Transplant Date: 2009-12-15 Impact factor: 5.992
Authors: Meredith C Foster; Nimrta Ghuman; Shih-Jen Hwang; Joanne M Murabito; Caroline S Fox Journal: Am J Kidney Dis Date: 2012-08-15 Impact factor: 8.860
Authors: K Wattanakit; A R Folsom; M H Criqui; H J Kramer; M Cushman; S Shea; A T Hirsch Journal: Atherosclerosis Date: 2008-02-20 Impact factor: 5.162
Authors: David S Knopman; Thomas H Mosley; Kent R Bailey; Clifford R Jack; Gary L Schwartz; Stephen T Turner Journal: J Neurol Sci Date: 2008-04-28 Impact factor: 3.181
Authors: Kenneth J Mukamal; Joseph Tremaglio; David J Friedman; Joachim H Ix; Lewis H Kuller; Russell P Tracy; Martin R Pollak Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-03 Impact factor: 8.311
Authors: Joshua I Barzilay; Petra Buzkova; Michael G Shlipak; Nisha Bansal; Pranav Garimella; Kenneth J Mukamal Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053